

Electronic Acknowledgement Receipt

EFS ID:	1018281
Application Number:	10567879
Confirmation Number:	2382
Title of Invention:	An antisense oligonucleotide to inhibit melanoma inhibitory activity mia
First Named Inventor:	Karl-Hermann Schlingensiepen
Customer Number:	26875
Filer:	Beverly A. Lyman/Juile Lape
Filer Authorized By:	Beverly A. Lyman
Attorney Docket Number:	VKSW05
Receipt Date:	06-APR-2006
Filing Date:	
Time Stamp:	11:02:33
Application Type:	U.S. National Stage under 35 USC 371
International Application Number:	

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Preliminary Amendment	VKSW-05_Preliminary_AMD _Typog_error.pdf	44969	no	1

Warnings:	
Information:	
Total Files Size (in bytes):	44969
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>	